Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Black Diamond Therapeutics, Inc. (BDTX) had Normalized Income after Taxes of $-9.90M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-9.90M |
|
-- |
|
-- |
|
$12.06M |
|
$-12.06M |
|
$2.15M |
|
$-9.90M |
|
$-9.90M |
|
$-9.90M |
|
$-9.90M |
|
$-9.90M |
|
|
Normalized Income after Taxes |
$-9.90M |
$-12.06M |
|
$-12.03M |
|
57.37M |
|
57.37M |
|
$-0.17 |
|
$-0.17 |
|
| Balance Sheet Financials | |
$115.39M |
|
$0.31M |
|
$9.63M |
|
$125.03M |
|
$15.84M |
|
-- |
|
$13.10M |
|
$28.94M |
|
$96.09M |
|
$96.09M |
|
$96.09M |
|
57.45M |
|
| Cash Flow Statement Financials | |
$-18.20M |
|
$16.38M |
|
$0.03M |
|
$21.82M |
|
$20.03M |
|
$-1.79M |
|
$2.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.31% |
|
-10.31% |
|
-7.92% |
|
-10.31% |
|
$1.67 |
|
$-0.32 |
|
$-0.32 |
|